KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Current Investments: 2019-2025

Historic Cash & Current Investments for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $955.0 million.

  • Royalty Pharma's Cash & Current Investments fell 4.36% to $955.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 11.56%. This contributed to the annual value of $987.2 million for FY2024, which is 99.31% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Cash & Current Investments is $955.0 million, which was up 48.04% from $645.1 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Cash & Current Investments peaked at $2.5 billion during Q2 2022, and registered a low of $495.3 million during Q4 2023.
  • Moreover, its 3-year median value for Cash & Current Investments was $987.2 million (2024), whereas its average is $1.2 billion.
  • In the last 5 years, Royalty Pharma's Cash & Current Investments skyrocketed by 976.21% in 2021 and then plummeted by 71.07% in 2023.
  • Quarterly analysis of 5 years shows Royalty Pharma's Cash & Current Investments stood at $1.6 billion in 2021, then climbed by 6.53% to $1.7 billion in 2022, then plummeted by 71.07% to $495.3 million in 2023, then soared by 99.31% to $987.2 million in 2024, then dropped by 4.36% to $955.0 million in 2025.
  • Its Cash & Current Investments was $955.0 million in Q3 2025, compared to $645.1 million in Q2 2025 and $1.1 billion in Q1 2025.